Abstract:Background Modified-Vaccinia-Ankara Bavarian Nordic (MVA-BN) vaccine has been recommended to tackle the mpox epidemic 2022-2023 and its resurgence in 2024. Although its effectiveness has been estimated to range between 36-86%, the persistence of protection is still unknown. Aims of this study is to assess the immune response one year after vaccination with MVA-BN. Methods Observational prospective study at the National Institute for Infectious Diseases in Rome. All people at high risk for mpox infection who received MVA-BN as pre-exposure prophylaxis were enrolled. People previously primed with smallpox vaccination received a single-dose course of MVA-BN, while non-primed received a two-dose course. Blood samples were collected at the time of each dose and one, six and 12 months after vaccination. MPXV-specific IgG and neutralizing antibody (nAb) titers were assessed by immunofluorescence and plaque neutralization tests, respectively. Interferon-gamma producing T-cell specific response to the MVA-BN vaccine was analyzed by ELISpot assay. Antibody titers at pre- and post-vaccination were compared using the Friedman tests. Mann Whitney test was used to compare antibody titers in PLWH vs PLWoH. Wilcoxon and Mann-Whitney non-parametric tests were used to compare T-cells specific response to the MVA-BN vaccine for intra and inter-group differences, respectively. Results Fifty high-risk people were included. All were men, with 94% self-reporting having sex with men. The median age was 50 years (IQR 45-57), and 21 (42%) were people living with HIV (PLWH), all on antiretroviral therapy, and 71% with a CD4 cell count higher than 500 mmc. 25 (50%) have been primed with previous smallpox vaccination. In non-primed people, anti-MPXV IgG titers significantly increased from T1 to T3 and, despite a slight reduction, were still higher than T1 up to T4 and then gradually decreased until T5, when 64% of sera were still reactive. MPXV-nAb titers peaked at T3 and then dropped, with 56% and 32% of sera reactive at T4 and T5, respectively. IFN-g; production by MVA-BN-specific T-cells progressively rose across time, peaked at T3, and remained significantly higher than the baseline after 6 and 12 months from vaccination. A single-dose course of MVA-BN vaccination in smallpox-primed participants elicited an early increase in IgG and nAb titers, which remained significantly higher than baseline after 6 and 12 months. MPXV-nAbs were detected in 80% and 72% of vaccinees at T4 and T5, respectively. A similar improvement and maintenance were observed for the MVA-BN-specific T-cell response. No evidence for a difference in both humoral and cellular responses was found between PLWH and PLWoH in our cohort. Conclusions One year after vaccination, our data showed the persistent detectability of low levels of nAb against MPXV in one-third of non-primed individuals. At the same time, humoral response was still detectable in most previously vaccinated participants. Concurrently, the MVA-BN-specific T-cell response was robust and persistent.

The Two-dose MVA-BN Mpox Vaccine Induces a Nondurable and Low Avidity MPXV-specific Antibody Response

Year-long assessment of the immune response elicited by MVA-BN vaccine

Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination

Vaccines against mpox: MVA-BN and LC16m8

Old and new mpox vaccine

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines

Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

MPXV Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to MVA-BN Vaccination

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus

Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023

Effectiveness and Safety of the MVA–BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc)

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates

Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)

MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings

Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease

Orthopoxvirus-specific antibodies wane to undetectable levels one year after MVA-BN vaccination of at-risk individuals

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge

Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL—March 2023–June 2023

Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study